Advanced in Metastatic Brain Tumor

Dr. Christine H. Chung

Oncology
H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc
4101 Jim Walter Blvd, 
Tampa, FL 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Advanced in Metastatic Brain Tumor
H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc
4101 Jim Walter Blvd, 
Tampa, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Christine Chung is an Oncologist in Tampa, Florida. Dr. Chung is rated as an Advanced provider by MediFind in the treatment of Metastatic Brain Tumor. Her top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Polymorphous Low Grade Adenocarcinoma, Epithelial-Myoepithelial Carcinoma, Salivary Gland Tumors, and Thyroidectomy. Dr. Chung is currently accepting new patients.

Her clinical research consists of co-authoring 226 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has participated in 1 clinical trial in the study of Metastatic Brain Tumor.

Specialties
Oncology
Licenses
Internal Medicine in TN
Languages Spoken
English
Korean
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MVP Health
  • EPO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

H LEE MOFFITT CANCER CTR AND RES INST LIFE TIME CANCER SCRN CTR INC
4101 Jim Walter Blvd, Tampa, FL 33607
Other Locations
H LEE MOFFITT CANCER CTR AND RES INST LIFE TIME CANCER SCRN CTR INC
12902 Usf Magnolia Dr, Tampa, FL 33612

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

Feasibility of Generating Novel Therapeutic Strategies Based on Evolutionary Tumor Board in Cancer Patients
Feasibility of Generating Novel Therapeutic Strategies Based on Evolutionary Tumor Board in Cancer Patients
Enrollment Status: Recruiting
Publish Date: October 01, 2025
Intervention Type: Other
A Phase I/II Study of Concurrent Cetuximab and Nivolumab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
A Phase I/II Study of Concurrent Cetuximab and Nivolumab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: October 10, 2025
Intervention Type: Drug
Study Drugs: Nivolumab, Cetuximab
Study Phase: Phase 1/Phase 2
M4OC-Prevent 2.0: Phase IIb Trial of Metformin for Oral Cancer Prevention
M4OC-Prevent 2.0: Phase IIb Trial of Metformin for Oral Cancer Prevention
Enrollment Status: Active_not_recruiting
Publish Date: September 29, 2025
Intervention Type: Drug, Procedure
Study Drug: Metformin Hydrochloride
Study Phase: Phase 2
A Phase 1b Trial of the IRX-2 Regimen and Durvalumab (MEDI4736), in Patients With Incurable Head and Neck Squamous Cell Carcinoma
A Phase 1b Trial of the IRX-2 Regimen and Durvalumab (MEDI4736), in Patients With Incurable Head and Neck Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: September 19, 2025
Intervention Type: Drug
Study Drugs: Durvalumab, IRX-2
Study Phase: Phase 1
Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Active_not_recruiting
Publish Date: September 18, 2025
Intervention Type: Procedure, Drug, Radiation
Study Drug: Birinapant
Study Phase: Phase 1
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2
Effect of Prolonged Nightly Fasting (PNF) on Immunotherapy Treatment Outcomes in Patients With Advanced Head and Neck Cancer (HNSCC)-Role of Gut Microbiome
Effect of Prolonged Nightly Fasting (PNF) on Immunotherapy Treatment Outcomes in Patients With Advanced Head and Neck Cancer (HNSCC)-Role of Gut Microbiome
Enrollment Status: Completed
Publish Date: August 21, 2025
Intervention Type: Behavioral
Study Phase: Not Applicable
Use of a Proliferation Saturation Index to Determine Personalized Radiotherapy Fractionation for Patients With HPV+ Oropharyngeal Cancers
Use of a Proliferation Saturation Index to Determine Personalized Radiotherapy Fractionation for Patients With HPV+ Oropharyngeal Cancers
Enrollment Status: Completed
Publish Date: August 17, 2025
Intervention Type: Radiation
Study Phase: Not Applicable
Targeted Intraoperative Radiotherapy United States (TARGIT-US) Phase IV Registry Trial: A Registry Trial of Targeted Intraoperative Radiation Therapy Following Breast-conserving Surgery
Targeted Intraoperative Radiotherapy United States (TARGIT-US) Phase IV Registry Trial: A Registry Trial of Targeted Intraoperative Radiation Therapy Following Breast-conserving Surgery
Enrollment Status: Active_not_recruiting
Publish Date: February 05, 2025
Intervention Type: Radiation, Other
Study Phase: Not Applicable
A Phase II Trial of Pembrolizumab and Cabozantinib in Patients With RM SCCHN
A Phase II Trial of Pembrolizumab and Cabozantinib in Patients With RM SCCHN
Enrollment Status: Active_not_recruiting
Publish Date: February 05, 2025
Intervention Type: Drug, Biological
Study Drugs: Cabozantinib, Pembrolizumab
Study Phase: Phase 2
A Randomized, Phase II Study of Ficlatuzumab With or Without Cetuximab in Patients With Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Randomized, Phase II Study of Ficlatuzumab With or Without Cetuximab in Patients With Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: September 04, 2024
Intervention Type: Drug, Biological
Study Drugs: Ficlatuzumab, Cetuximab
Study Phase: Phase 2
A Randomized Phase 2 Trial of Neoadjuvant and Adjuvant Therapy With the IRX 2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity
A Randomized Phase 2 Trial of Neoadjuvant and Adjuvant Therapy With the IRX 2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity
Enrollment Status: Completed
Publish Date: January 30, 2024
Intervention Type: Drug, Dietary supplement, Biological
Study Drugs: IRX-2, Cyclophosphamide, Indomethacin, Omeprazole
Study Phase: Phase 2
The IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors: A Phase 1b Study to Evaluate the Safety, Determine Recommended Phase 2 Dose (RP2D), and Investigate the Biologic and Clinical Activity
The IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors: A Phase 1b Study to Evaluate the Safety, Determine Recommended Phase 2 Dose (RP2D), and Investigate the Biologic and Clinical Activity
Enrollment Status: Completed
Publish Date: April 14, 2023
Intervention Type: Drug
Study Drugs: IRX-2, Nivolumab
Study Phase: Phase 1
A Phase I Dose Escalation Trial of Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of the Head and Neck
A Phase I Dose Escalation Trial of Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of the Head and Neck
Enrollment Status: Completed
Publish Date: January 19, 2023
Intervention Type: Radiation, Drug
Study Drug: Cisplatin
Study Phase: Phase 1
A Single Arm Phase II Study of Cemiplimab-rwlc in Immunocompromised Patients With Unresectable Locally Recurrent and/or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC)
A Single Arm Phase II Study of Cemiplimab-rwlc in Immunocompromised Patients With Unresectable Locally Recurrent and/or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC)
Enrollment Status: Terminated
Publish Date: November 04, 2022
Intervention Type: Drug
Study Drug: Cemiplimab-RWLC
Study Phase: Phase 2
View 14 Less Clinical Trials

226 Total Publications

Hong Kong's early detection, assessment, and response system (S-EDAR) for infectious disease outbreak: abridged secondary publication.
Hong Kong's early detection, assessment, and response system (S-EDAR) for infectious disease outbreak: abridged secondary publication.
Journal: Hong Kong medical journal = Xianggang yi xue za zhi
Published: September 15, 2025
Similar Doctors
Zeynep Eroglu
Distinguished in Metastatic Brain Tumor
Dr. Zeynep Eroglu
Hematology | Oncology
Distinguished in Metastatic Brain Tumor
Dr. Zeynep Eroglu
Hematology | Oncology

H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc

12902 Usf Magnolia Dr, 
Tampa, FL 
 (8.7 miles away)
888-860-2778
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Zeynep Eroglu is a Hematologist and an Oncologist in Tampa, Florida. Dr. Eroglu is rated as an Elite provider by MediFind in the treatment of Metastatic Brain Tumor. Her top areas of expertise are Melanoma, Merkel Cell Carcinoma, Primitive Neuroectodermal Tumor (PNET), and Posterior Fossa Tumor.

Advanced in Metastatic Brain Tumor
Dr. Patrick T. Grogan
Oncology
Advanced in Metastatic Brain Tumor
Dr. Patrick T. Grogan
Oncology

H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc

12902 Usf Magnolia Dr, 
Tampa, FL 
 (8.7 miles away)
888-860-2778
Experience:
9+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Patrick Grogan is an Oncologist in Tampa, Florida. Dr. Grogan has been practicing medicine for over 9 years and is rated as a Distinguished provider by MediFind in the treatment of Metastatic Brain Tumor. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

Nikhil Khushalani
Distinguished in Metastatic Brain Tumor
Dr. Nikhil Khushalani
Hematology | Oncology
Distinguished in Metastatic Brain Tumor
Dr. Nikhil Khushalani
Hematology | Oncology

H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc

12902 Usf Magnolia Dr, 
Tampa, FL 
 (8.7 miles away)
888-860-2778
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nikhil Khushalani is a Hematologist and an Oncologist in Tampa, Florida. Dr. Khushalani is rated as a Distinguished provider by MediFind in the treatment of Metastatic Brain Tumor. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Metastatic Brain Tumor, and Neuroendocrine Tumor.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chung's expertise for a condition
ConditionClose
View All 22 Advanced Conditions
View All 17 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile